MAPT and Alzheimer disease: As recently proposed for AD patients [40], it is conceivable that also in mouse models of AD, characterized by robust amyloid deposition and tau hyperphosphorylation, an extended period of lithium treatment might be necessary to counteract the disrupted Wnt/β-catenin signalling, neurogenesis and cognitive impairments.